PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its ...

PTC Therapeutics, Inc.’s PTCT share price has surged by 6.72%, which has investors questioning if this is right time to sell.

PTC today announced two new offerings from its cloud-native Onshape® computer-aided design (CAD) and product data management (PDM) platform: Onshape AI Advisor, an intelligent, generative AI-powered ...

In a report released today, Eric Joseph from J.P. Morgan maintained a Hold rating on Verve Therapeutics (VERV – Research Report), with a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Learn more about whether Neurocrine Biosciences, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (PTCT – Research Report) ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Detailed price information for Nanobiotix S.A. ADR (NBTX-Q) from The Globe and Mail including charting and trades.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...